NFE2L2 and hepatocellular carcinoma: Additionally, tiliroside synergistically combines with sorafenib to inhibit Tank-binding kinase (TBK1) activity, prompting Keap1-mediated Nrf2 ubiquitination and degradation, leading to ferroptosis in hepatocellular carcinoma cells[45].